References

  1. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
  2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-4600.
  3. Data on File, 1196503. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  4. Data on File, 1198501. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  5. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  6. Ghany M, Hoofnagle JH. Approach to the patient with liver disease. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008:1918-1923.
  7. Howell A. Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator? Int J Gynecol Cancer. 2006; 16 (suppl 2): 521-523.
  8. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7(1):17-28.
  9. Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer. 2005;6(suppl 1):S5-S8.
  10. Dowsett M, Nicholson Ri, Pietras RJ. Biologic characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Treat Res. 2005;93:S11-S18.
  11. Parker MG. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat. 1993;26(2):131-137.
  12. Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L; for the Trial 0020 and 0021 Investigators. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003;79(2):207-211.
  13. Gutteridge E, Robertson JFR, Cheung KL, Pinder S, Wakeling A. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer–final results. Breast Cancer Res Treat. 2004;88(suppl 1):S177. Abstract 4086.

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

IMPORTANT SAFETY INFORMATION:
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.

Click Here for Additional Safety Information